# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and announces Price Ta...
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.34...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...